Abstract: Aspects of the invention are directed towards method system and devices assisting a user in providing seamless access to a user through an access point of the access system. The invention describes estimating various factors such as time, distance, and signal strength enabling frictionless access to the user. The invention describes adjusting the time interval and the signal strength according to the needs of the user. Various other embodiments of the invention describes estimating a threshold signal strength and time interval based on a distance of the user from the access point.

Abstract: In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.

Abstract: In some aspects, the disclosure relates to compositions and methods of engineering a transgene. In some embodiments, the disclosure provides self-regulating recombinant nucleic acids, viral vectors and pharmaceutical compositions comprising a MeCP2 transgene. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases and disorders associated with a loss of function mutation, for example Rett syndrome.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: Methods of treating subjects having disorders associated with mutations in the FXN gene and/or having reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).

Abstract: The disclosure relates to methods and compositions for regulating expression of DUX4. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy).

Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.

Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: A wireless device may be configured to operate in one of two modes where each mode uses a different channel list to perform operations in accordance with the IEEE 802.11 standard. In a first mode, the wireless device operates as an access point that sets up channels using one channel list in order to facilitate communications within a basic service set (BSS). In a second mode, the wireless device uses a second channel list to operate as a station and scan for a BSS. The first channel list contains a subset of the channels contained in the second channel list. The channels in each respective channel list may be reconfigured to adapt to changes in the configuration of a BSS and the devices communicating therein.

Abstract: A wireless device may be configured to operate in one of two modes where each mode uses a different channel list to perform operations in accordance with the IEEE 802.11 standard. In a first mode, the wireless device operates as an access point that sets up channels using one channel list in order to facilitate communications within a basic service set (BSS). In a second mode, the wireless device uses a second channel list to operate as a station and scan for a BSS. The first channel list contains a subset of the channels contained in the second channel list. The channels in each respective channel list may be reconfigured to adapt to changes in the configuration of a BSS and the devices communicating therein.

Abstract: The present application describes a system and method for validating a detachable antenna which may include, coupling a detachable antenna to a wireless device, providing an antenna identification code of the detachable antenna to the wireless device, determining if the antenna identification code of the detachable antenna is a valid antenna identification code for the wireless device and enabling operation of the wireless device if the antenna identification code of the detachable antenna is a valid antenna identification code for the wireless device. The operation of the wireless device may additionally be disabled if it is subsequently determined that the detachable antenna connected to the wireless device is no longer a valid antenna or if it is determined that the detachable antenna has been previously used by another wireless device.

Abstract: A set of global location signals, an SBAS (Satellite Based Augmentation System), or an ACI (ambient country identifier) signal can be used to automatically provide location awareness for a WLAN device. If one of the set of global location signals, the SBAS signal, or the ACI signal is detected, then the WLAN device can configure itself to comply with channel and power settings for the country/region having the detected signal(s). After configuration, the WLAN device can be “locked” to the country/region having the signal(s), thereby ensuring legal operation of the WLAN device even after subsequent restarts. If one of the signals is not detected, then the WLAN device can be configured in a default mode, e.g. an “open mode” in which end users can configure the WLAN device by entering a country of operation or a “common mode” in which the channel and transmit power settings meet global spectrum usage requirements.

Abstract: An ambient country identifier (ACI) signal can be used to automatically provide location awareness for a WLAN device. If an ACI signal is detected, then the WLAN device can configure itself to comply with channel and power settings for the country having the detected ACI signal. After detection of the ACI signal, the WLAN device can be “locked” to the country having that ACI signal, thereby ensuring legal operation of the WLAN device even after subsequent restarts. If an ACI signal is not detected, then the WLAN device can be configured in a default mode, e.g. an “open mode” in which end users can configure the WLAN device by entering a country of operation or a “common mode” in which the channel and transmit power settings meet global spectrum usage requirements.